secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950170-23-006132
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharmaceuticals appoints Yong Ben, M.D., MBA to Board of Directors
-------------------------------------------------------------------------

- Dr. Ben appointed to board effective March 1, 2023; press release issued March 6, 2023.
- He brings over 20 years of oncology drug development experience, including roles at BeiGene, BioAtla, and AstraZeneca.
- Initial option grant of 5,307 shares; annual cash retainer of $40,000 and annual stock option grant.
- Company also entered into standard indemnification agreement with Dr. Ben.
- Appointment supports Corbus' precision oncology pipeline including CRB-701 and CRB-601.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/0000950170-23-006132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/crbp-20230301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer